Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Summary

Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment. This study will enroll approximately 90 male and female pediatric subjects clinically diagnosed with Tourette Syndrome.

Timeline

Start

2016-03-23

Primary completion

2017-04-14

Completion

2017-04-14

Drugs

Indications